Skin probiotics to treat netherton syndrome
Ended Project Grant Awarded Last action
- Award ID
- R44AR082240
- Recipient
-
Resvita Bio Inc. UEI LE1LFZE6EMK5
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,033,762
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Place of performance
- Berkeley, CA 94704, USA
Award details come from USAspending.gov.
Description
- Abstract
- Netherton syndrome (NS) is a genetic disorder of significant severity impacting the skin, hair, and immune system. The condition arises from mutations within the SPINK5 gene, responsible for encoding lekti (lympho-epithelial kazal-type inhibitor), a serine protease inhibitor. Ordinarily, the skin's exfoliation process is modulated by the balance between these serine proteases and their inhibitors. Mutations in lekti lead to elevated serine protease activity, leading to the persistent skin condition associated with NS. Unfortunately, an FDA-approved therapy remains absent for this condition, with management of symptoms primarily relying on antibacterials, emollients, and corticosteroids. Most therapeutic efforts are to develop small molecule inhibitors, but systemic absorption of these long- lasting molecule often results in toxicity. We propose to genetically engineer a harmless bacterium to temporarily populate the skin and deliver lekti fragments, that normally have a short half-life, continuously. In our phase i sbir, we established the safety and feasibility of our topical application. In this phase II application, we fully develop our final cell therapy and show efficacy in diseased in vitro and murine models. This data will provide the crux of our pre-IND (investigational new drug) meeting with the FDA. Our platform for continuous production of peptide drugs on the skin surface has the potential to revolutionize the treatment of NS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $703,229 | |
| Original award | $1,330,533 |
Quick answers
Who received award R44AR082240?
R44AR082240 was awarded to Resvita Bio Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 15, 2022.
How much is award R44AR082240 worth?
$2,033,762 has been obligated on R44AR082240.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award